ARTICLE | Company News
Merck provides pipeline update
July 29, 2011 11:46 PM UTC
In its 2Q11 results Friday, Merck & Co. Inc. (NYSE:MRK) updated its pipeline and said it discontinued development of telcagepant (MK-0974), a calcitonin gene-related peptide (CGRP) receptor antagonist that was in Phase III testing for migraine. Details were not disclosed.
On the regulatory front, FDA accepted for review an sNDA for Dulera mometasone/formoterol to treat chronic obstructive pulmonary disease (COPD). The PDUFA date is not disclosed. The product is approved for asthma. ...